Men's health in primary care

Men’s health consultations often begin with one symptom but reveal linked cardiovascular, urological, sexual, reproductive or psychological needs. Reduce practical and stigma-related barriers, explain why sensitive questions matter and avoid a generic “male MOT”.

Use anatomy and exposure rather than assumptions. Trans women may have a prostate; trans men may require contraception or cervical screening. Ask respectfully about organs, hormones and surgery only when relevant. Offer a private consultation, a chaperone for intimate examination and a professional interpreter. Sexual orientation does not predict behaviour, STI exposure or reproductive intention.

Triage acute presentations. Sudden severe unilateral scrotal pain, especially with nausea, a high or horizontal testis or absent cremasteric response, requires immediate surgical assessment for torsion. Do not delay a strongly suspicious presentation for routine ultrasound. Acute urinary retention requires prompt bladder assessment and catheter management by an appropriately trained clinician, with urgent escalation for sepsis, renal impairment, neurological deficit or difficult catheterisation.

Lower urinary tract symptoms are classified as storage, including urgency, frequency and nocturia; voiding, including poor stream, hesitancy and straining; and post-micturition, including dribble and incomplete emptying. Establish duration, bother and effect, fluid and caffeine intake, medicines, infection symptoms, haematuria, pain, constipation, diabetes, neurological features and sexual function. Use a frequency-volume chart when it will change assessment.

Examination is directed. Assess abdomen and bladder, external genitalia when indicated, and perform digital rectal examination when prostate pathology is relevant and consent is given. DRE describes size, consistency, symmetry and nodularity but neither rules cancer in nor out. Check urinalysis for blood, glucose, protein, leucocytes and nitrites as clinically appropriate; interpret findings with symptoms and avoid treating asymptomatic results reflexively.

NICE CG97 recommends offering men with bothersome LUTS an assessment that includes history, medicines review, physical examination and urine dipstick. At initial assessment, do not routinely offer cystoscopy, upper-tract imaging, flow-rate measurement or post-void residual unless there is a specific indication. PSA testing is considered when LUTS suggest bladder-outlet obstruction from benign enlargement, the prostate feels abnormal or the person is concerned about prostate cancer after counselling.

PSA decision making must cover false positive and false negative results, benign and transient causes of elevation, possible MRI and biopsy, overdiagnosis and treatment harms, as well as the possibility of earlier cancer detection. Check current NICE suspected-cancer thresholds and local pathway because interpretation is age- and context-dependent. If infection or recent manipulation may distort the result, manage that context and time testing using current guidance rather than a fixed remembered rule.

Screening policy is distinct from symptomatic testing. As of 7 September 2026, the UK National Screening Committee does not recommend population screening for prostate cancer. It has, however, recommended targeted PSA testing every two years between ages 45 and 61 for men with a pathogenic BRCA2 variant and a family history of breast, ovarian, pancreatic or prostate cancer. This narrow recommendation does not justify opportunistic population testing, and clinicians should check whether and how the programme is implemented locally.

Visible haematuria, recurrent or persistent urinary infection, renal impairment suspected from lower-tract dysfunction, a hard irregular prostate, neurological bladder features or urinary retention require appropriate referral. Use current NICE NG12 criteria for suspected cancer rather than inventing an age threshold. Safety-net patients with persistent symptoms even after an initially reassuring urinalysis, PSA or examination.

Erectile dysfunction assessment covers onset, situational pattern, libido, morning erections, relationship context, genital symptoms, medicines, alcohol and psychological factors. Examine and test according to suspected cause. Because vascular endothelial disease may present first as erectile dysfunction, assess blood pressure, diabetes and cardiovascular risk. Phosphodiesterase-5 inhibitors require interaction and cardiovascular assessment; concurrent nitrates are a critical contraindication.

Premature ejaculation, reduced desire and ejaculatory problems deserve the same biopsychosocial approach. Testosterone testing is not a screening test for fatigue alone. When hypogonadism is suspected, use correctly timed measurements and confirm low results under current endocrine guidance before treatment; acute illness and obesity can lower concentrations. Fertility assessment starts with duration, intercourse and ejaculation, reproductive history, testicular injury, medicines and both partners rather than assuming a single-person cause.

Testicular lumps require direct examination. A hard intratesticular mass is suspicious for cancer and needs urgent ultrasound or referral under current pathways; a clearly separate epididymal cyst has a different pathway, but uncertainty should not be dismissed. Give testicular self-awareness advice focused on prompt review of a new persistent lump, enlargement or heaviness rather than promising that routine self-examination prevents death.

Mental-health assessment should be explicit. Ask about low mood, anhedonia, agitation, sleep, shame, alcohol or drug use, financial and relationship stress, self-harm and suicide plans. A calm presentation does not prove safety. Explore access to means, protective factors and immediate support, share information when necessary to protect life under professional guidance, and agree a same-day safety plan or urgent mental-health assessment when risk is high.

Prevention should be evidence-based. In England the NHS AAA programme invites men for screening in the year they turn 65; men older than 65 who have not been screened can self-refer. Cardiovascular prevention, bowel screening, vaccination and smoking support follow current nation-specific eligibility, not a special all-purpose men’s panel. Check blood pressure opportunistically and make access practical.

End by agreeing one or two actions that matter. Document examination consent, counselling before PSA, the reason for tests, and who will act on results. Give specific return advice for retention, fever, visible blood, worsening pain, a new testicular lump or mental-health crisis. A test is not complete until the result and downstream decision reach the patient.